Dr. Reddy's launches Propofol generic in US market

Our Bureau Hyderabad | Updated on January 24, 2019 Published on January 24, 2019

Pharma major Dr Reddy’s Laboratories Ltd has launched Propofol Injectable Emulsion, a therapeutic equivalent generic version of Diprivan (propofol) Injectable Emulsion, approved by the U.S. Food and Drug Administration (USFDA).

Dr. Reddy’s uses distribution controls to market Propofol Injectable Emulsion and will not accept orders from correctional facilities and prison systems whose intended use of the product is to aid in lethal injection.

The Diprivan brand and generic had US sales of approximately $310 million for the most recent twelve months ending in November 2018 according to IMS Health, according to a release.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on January 24, 2019
This article is closed for comments.
Please Email the Editor